MIRA INFORM REPORT

 

 

Report Date :

10.09.2011

 

IDENTIFICATION DETAILS

 

Name :

LACTOSE INDIA LIMITED

 

 

Registered Office :

Survey No. 6, Village Poicha (Rania), Savli, Dist. Vadodara – 397 080, Gujarat

 

 

Country :

India

 

 

Financials (as on) :

31.03.2010

 

 

Date of Incorporation :

11.03.1991

 

 

Com. Reg. No.:

04-15186

 

 

CIN No.:

[Company Identification No.]

L15201GJ1991PLC015186

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

MUML01469G

 

 

Legal Form :

Public Limited Liability company. The company’s shares are listed on the Stock Exchange

 

 

Line of Business :

Manufacturer and Trader of Pharmaceutical Products

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B (26)

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Maximum Credit Limit :

USD 430000

 

 

Status :

Moderate

 

 

Payment Behaviour :

Slow

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company having moderate track. Profitability of the company appears to be low. However, trade relations are reported as fair. Business is active. Payments are reported as to be slow.

 

The company can be considered for business dealings with some caution.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – April 1, 2010

 

Country Name

Previous Rating

(31.12.2009)

Current Rating

(01.04.2010)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

LOCATIONS

 

Registered Office :

Survey No. 6, Village Poicha (Rania), Savli, Dist. Vadodara – 397 080, Gujarat, India

Tel. No.:

91-2667-244308/244225/244729/ 66952701

E-Mail :

lactose@vsnl.com ,  sangitam@vsnl.net

Website :

http://www.lactoseindia.com

 

 

Corporate Office :

211, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai – 400 053, Maharashtra, India

Tel. No.:

91-22-66952701-03

Fax No.:

91-22-66952704

E-Mail :

lactose@vsnl.com / sangitam@vsnl.net

 

 

Administrative Office :

5th Floor, R C Dutt Road, Alkapuri, Baroda-390005, Gujarat, India

Tel. No.:

91-265-2330825/2840397

Fax No.:

91-265-2840397

 

 

Factory 1 :

Survey No. 6, Village Poicha (Rania), Savli, Dist. Vadodara – 397 080, Gujarat, India

Tel. No.:

91-2667-244308/244225/244729

E-Mail :

lactose@vsnl.com ,  sangitam@vsnl.net

Area :

10121 sq. mtrs.

 

 

Sales Office :

10, Shah and Nahar Industrial Estate, Off. E. Moses Road, Worli Naka, Mumbai-400018, Maharashtra, India

Tel. No.:

91-22-24921953/24946148/24973953

Fax No.:

91-22-24939838

 

 

DIRECTORS

 

As on 31.03.2010

Name :

Mr. S M Maheshwari

Designation :

Chairman and Managing Director

 

 

Name :

Mr. Atul Maheshwari

Designation :

Executive Director

Address :

52/A, Aashit Apartments, Stan Burg Est. Juhu, Mumbai-400049, Maharashtra, India

Date of Birth/Age :

2nd July, 1965

Date of Appointment :

11th March, 1991

 

 

Name :

Mr. O P Singhi

Designation :

Director

 

 

Name :

Mr. G K Sarda

Designation :

Director

 

 

Name :

Mr. Pramod Kalani

Designation :

Additional Director

 

 

 

 

 

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 30.06.2011

 

Names of Shareholders

No. of Shares

Percentage of Holding

(A) Shareholding of Promoter and Promoter Group

 

 

(1) Indian

 

 

Individuals / Hindu Undivided Family

1,567,650

21.52

Any Others (Specify)

534,832

7.34

Group Companies

534,832

7.34

Sub Total

2,102,482

28.86

(2) Foreign

 

 

Total shareholding of Promoter and Promoter Group (A)

2,102,482

28.86

(B) Public Shareholding

 

 

(1) Institutions

 

 

Financial Institutions / Banks

77,920

1.07

Sub Total

77,920

1.07

(2) Non-Institutions

 

 

Bodies Corporate

134,988

1.85

Individuals

 

 

Individual shareholders holding nominal share capital up to Rs.0.100 millions

3,930,872

53.96

Individual shareholders holding nominal share capital in excess of Rs.0.100 millions

255,817

3.51

Any Others (Specify)

782,921

10.75

Non Resident Indians

782,721

10.74

Clearing Members

200

--

Sub Total

5,104,598

70.07

Total Public shareholding (B)

5,182,518

71.14

Total (A)+(B)

7,285,000

100.00

(C) Shares held by Custodians and against which Depository Receipts have been issued

-

-

Total (A)+(B)+(C)

7,285,000

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer and Trader of Pharmaceutical Products

 

 

Products :

Pharmaceutical Products - Lactose Powder

 

 

Imports from :

Europe and USA (mainly from Holland and New Zealand)

 

 

Terms :

 

Purchasing :

against L/C terms

 

 

 

 

 

PRODUCTION STATUS (As on 31.03.2009)

 

Particulars

 

Unit

Installed Capacity

Actual Production

 

 

 

 

Lactose

 

MT

 

937.675

Machine

 

RY

1500 MT

--

Nergy Sachets

 

Nos.

 

--

Strength Plus Sachet

 

Nos.

 

--

Fabric

 

Mtrs.

 

1138420

 

 

GENERAL INFORMATION

 

No. of Employees :

About 120

 

 

Bankers :

v      State Bank of India

Industrial Finance Branch, Shivsagar Estate, Worli (South),

Mumbai – 400 018

 

v      State Bank of India

R. C. Dutt Road, Vadodara – 397 080, Gujarat, India

 

v      Oriental Bank of Commerce

Prabhadevi Branch, Aman Chambers, 1st Floor, Veer Savarkar

Marg, Opp New Passport Office, Prabhadevi, Mumbai – 400 025, 

Maharashtra, India

 

 

 

Banking Relations :

 

 

 

Auditors :

 

Name :

K. M. Tulsian and Associates

Chartered Accountants

Address :

201, 204 Rajeshri Accord, Telly Cross Lane, S. N. Road, Andheri (East), Mumbai – 400 069, Maharashtra, India

 

 

CAPITAL STRUCTURE

 

As on 29.09.2010

 

Authorised Capital : Rs.100.000 millions

 

Issued, Subscribed & Paid-up Capital :Rs.72.850 millions

 

 

 

 

 

 

 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2010

31.03.2009

31.03.2008

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

69.400

66.100

55.200

2] Share Application Money

37.300

32.400

32.000

3] Reserves & Surplus

0.300

0.700

0.000

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

107.000

99.200

87.200

LOAN FUNDS

 

 

 

1] Secured Loans

61.500

66.800

77.900

2] Unsecured Loans

4.100

8.300

11.400

TOTAL BORROWING

65.600

75.100

89.300

DEFERRED TAX LIABILITIES

12.700

10.700

09.800

 

 

 

 

TOTAL

185.300

185.000

186.300

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

137.200

127.600

131.200

Capital work-in-progress

0.000

3.600

0.000

 

 

 

 

INVESTMENT

3.000

3.200

2.200

DEFERREX TAX ASSETS

0.000

0.500

0.300

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

13.500
17.400

22.500

 

Sundry Debtors

45.400
27.700

40.600

 

Cash & Bank Balances

3.500
3.800

2.800

 

Other Current Assets

0.000

0.000

0.000

 

Loans & Advances

63.200
67.200

45.100

Total Current Assets

125.600

116.100

111.000

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Sundry Creditors

 

Other Current Liabilities

79.000
62.400

55.300

 

Provisions

1.500
3.600

3.100

Total Current Liabilities

80.500
66.000

58.400

Net Current Assets

45.100
50.100

52.600

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.000

0.000

 

 

 

 

TOTAL

185.300

185.000

186.300

 

 

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2010

31.03.2009

31.03.2008

 

SALES

 

 

 

 

 

Income

228.800

205.300

268.300

 

 

Other Income

11.000

1.400

5.000

 

 

TOTAL                                     (A)

239.800

206.700

273.300

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Raw Materials

132.800

111.000

189.500

 

 

Power & Fuel

19.900

19.500

12.500

 

 

Employee Cost

14.700

18.600

12.300

 

 

Other Manufacturing Expenses

21.100

9.300

9.300

 

 

Selling and Administrative Expenses

22.700

21.000

24.100

 

 

Miscellaneous Expenses

1.500

2.300

2.500

 

 

Increase/(Decrease) in Finished Goods

(6.200)

(1.200)

0.100

 

 

TOTAL                                     (B)

206.500

180.500

250.300

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)      (C)

33.300

26.200

23.000

 

 

 

 

 

Less

FINANCIAL EXPENSES                         (D)

9.400

10.400

9.400

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

23.900

15.800

13.600

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

14.500

13.800

9.100

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                               (G)

9.400

2.000

4.500

 

 

 

 

 

Less

TAX                                                                  (H)

4.400

1.600

3.900

 

 

 

 

 

 

PROFIT AFTER TAX (G-H)                                (I)

5.000

0.400

0.600

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

25.900

25.500

24.900

 

 

 

 

 

 

BALANCE CARRIED TO THE B/S

30.900

25.900

25.500

 

 

 

 

 

 

Earnings Per Share (Rs.)

7.200

0.600

1.100

 

 

 

 

 

 

QUARTERLY RESULTS (UNAUDITED)

                                                                                                                                     (Rs. In Millions)

PARTICULARS

 

30.09.2010

31.12.2010

31.03.2011

30.06.2011

 

 

1st Quarter

2nd Quarter

3rd Quarter

4th Quarter

Net Sales

56.060

84.360

79.970

90.750

Total Expenditure

47.720

75.050

76.320

80.750

PBIDT (Excl OI)

8.340

9.310

3.650

10.000

Other Income

0.310

0.120

0.180

0.140

Operating Profit

8.650

9.430

3.830

10.140

Interest

2.140

2.120

2.260

2.070

Exceptional Items

0.000

0.000

1.230

0.000

PBDT

6.510

7.310

2.800

8.070

Depreciation

3.950

4.050

4.110

4.060

Profit Before Tax

2.560

3.260

(1.320)

4.010

Tax

0.400

1.000

(2.200)

1.230

Provisions and Contingencies

0.000

0.000

0.000

0.000

Profit After Tax

2.160

2.260

0.870

2.780

Extraordinary Items

0.000

0.000

0.000

0.000

Prior Period Expenses

0.000

0.000

0.000

0.000

Other Adjustment

0.000

0.000

0.000

0.000

Net Profit

2.160

2.260

0.870

2.780

 

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2010

31.03.2009

31.03.2008

PAT / Total Income

(%)

2.09
0.19

0.22

 

 

 
 

 

Net Profit Margin

(PBT/Sales)

(%)

4.11
0.97

1.68

 

 

 
 

 

Return on Total Assets

(PBT/Total Assets}

(%)

3.58
0.82

1.86

 

 

 
 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.09
0.02

0.05

 

 

 
 

 

Debt Equity Ratio

(Total Liability/Networth)

 

1.37
1.42

1.69

 

 

 
 

 

Current Ratio

(Current Asset/Current Liability)

 

1.56
1.76

1.90

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Company History:

 

Subject is an India-based company. The company is engaged in the manufacturing and trading of pharmaceutical products. They offer edible and pharmaceutical grade lactose, which is used as an ingredient in pharmaceutical products, as well as in the dairy, food, confectionery, and beverage industries. The company also manufactures dairy whitener, dairy calcium, whey powder, casein, caseinate, butter, and ghee. Further, they engage in the contract manufacture of pharmaceutical products. The company is having their manufacturing facilities located at Vadodara in Gujarat. This state of art manufacturing facilities for the manufacture of pharmaceutical formulations is in compliance with all international standards. The manufacturing facilities include wet granulation, Fluid bed drying, compaction, blending and coating facilities with the latest technology equipments. The company is well backed up by its excellent network of indenting agents in India i.e. Mumbai, Delhi, Chennai, Bangalore, Calcutta, Hyderabad and Ahmedabad. Lactose (India) Ltd was incorporated on March 1991 as a public limited company in the Vadodara district of Gujarat. The company set up a project to manufacture lactose IP/BP grade, an import substitute, with an installed capacity of 465 tpa at an estimated cost of Rs.45.000 millions. The unit was commissioned by Alfa Laval, Pune, a subsidiary of Alfa Laval, Sweden. In January 1994, the company commenced commercial production of Lactose. In the year 1994, the company undertook an expansion and forward integration programme involving the capacity expansion of lactose from 465 tpa to 1500 tpa. They also set up of a pharmaceutical formulation plant with three sections, namely capsule section, tablet section and indictable section. During the year 1995-96, the company started processing sweetened condenced milk for domestic supply and acid casein for exports. They had started the job work of condenced milk casein powder. During the year 2004-05, the company streamlined their pharmaceutical plant and entered into long-term contract manufacturing for one of the leading multinational company. They invested substantially in upgrading and renovating the Pharmaceutical facilities as per the requirement of the new Schedule M, as per the directives from the Food and Drug Administration. Also, they started a new equipment manufacture, assemble and export for Projects division in Kandla SEZ (Special Economic Zone). During the year 2006-07, the company undertook major expansion programme at their existing production site for manufacturing of value added product 'LACTULOSE' which is a forward integration of their existing product 'LACTOSE'. During the year 2007-08, the company successfully implemented the task undertaken last year and commissioned the new liquid orals division. During the year 2008-09, the company started manufacturing of Liquid Formulations.

 

REVIEW OF OPERATIONS:
 
During the year, the company achieved sales Rs.257.493 millions, (Previous Year Rs. 218.020 millions) showing a growth of 18.10 % compared to the previous year. The Company has earned a profit after tax of Rs.4.952 millions, compared to last year's profit of Rs.0.455 millions. The Company has achieved EPS  of Rs.0.71 against 0.07 in the previous year. A detailed analysis of the performance for the year has been included in the Management Discussion and Analysis, which forms part of the Annual Report.
 
The Company has also installed and commissioned Agro waste fired boiler and has applied for availing of Carbon Credits against the use of Agro waste instead of Fossil fuel.

 

MANAGEMENT DISCUSSION AND ANALYSIS
 
Industry Structure and Development:
 
The Indian economy has been witnessing a phenomenal growth since the last decade. The country is still holding its ground in the midst of the current global financial crisis. The world Economy is beginning to recover from one of the worst economic downturns in decades.
 
It is estimated that by 2015, the Indian Pharmaceutical Industry will rank amongst the top  10 in the world. A  healthy  competitive  structure  and international  approved facilities have served to encourage the  growth  of pharmaceutical industry.
 
Opportunities and Threats:
 
The Company  has started manufacturing of Liquid  Formulations.  Existing products  have  been  moved on to the International market  arena  and  the Company has received an excellent response to its product line. Though   the slow down in foreign countries remains a worry
 
Outlook:
 
The  Company  has  decided  to focus on products  and  markets  of  higher  profitability  only. The change in marketing strategy and exposure  in  the world  market  will enable us to become a global force to reckon  with.  They have  started exporting new products to Canada, Nigeria etc and the  demand for the products is very healthy.
 

 

 AS PER WEBSITE DETAILS

 

PROFILE

 

Subject forces home one strong promise "Only the best is good enough for their customers and good enough to carry their name" Products that leave the company's manufacturing facility in Vadodara, Gujarat, are sure to meet the exacting standards set by the company and its demanding customers.

 

Subject plant in Vadodara, Gujarat was commissioned by Alfa Laval, Pune (which is a subsidiary of Alfa Laval of Sweden) and was also given a 'thumbs up' by reputed dairy experts from the Netherlands in October 1991. Subsequently Alfa Laval, reputed dairy experts from Sweden and a joint commission from the Netherlands studied the plant and its working and confidently acknowledged the plant for its quality standards as well.

 

With its unparalled infrastructure of requisite equipment and dedicated work force, Lactose (India) Limited has a state of the art manufacturing facility for contract manufacturing of pharmaceutical products. The latest in its diverse interests is the manufacturing of pharmaceutical formulations for Aventis Pharma Limited.(earlier-Hoechst Marion Russell), for the purpose of domestic use and export to Russia.

 

This state of art manufacturing facilities for the manufacture of pharmaceutical formulations is in compliance with all international standards. The plant is approved under WHO-CGMP guidelines and also holds TUV certificate as an ISO 9001: 2000 company. The manufacturing facilities include wet granulation, Fluid bed drying, and compaction, blending and coating facilities with the latest technology equipments. The manufacturing facilities are well supported by its total in-house Quality Control set-up with latest Testing equipments and an up to date Microbiology Testing Laboratory. The Facility is supported by an equally competent and FDA approved Manufacturing professionals.

 

The company is forcefully led by a balanced combination of technical and industrial experts. Mr. S. S. Toshniwal - Chairman, brings in a wealth of industrial experience having diversified in businesses of varying natures ie trading, export and manufacturing. Over 30 years of unmatched experience in a global market have added to his experience.


Mr. S. M. Maheshwari - Managing Director, is the company's forefront in operations and brings his experience of over 35 years with pharmaceutical giants like Hoechst Marion Roussel, Abbott Labs, American Cyanamid and Warner Lambert. His vast experience in the manufacturing, quality assurance and operational competencies in real time management is quite unmatched.

 

Mr. Atul Maheshwari - Executive Director, with his MBA in marketing faculty from the USA, handles the marketing and sales portfolio for the company along with his focus on overall business and product development. His past experience includes the export of US products to India and the import of Indian dairy products to the US.

 

The executive team is well backed by a work force of devoted and skilled professionals.

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                  None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.46.38

UK Pound

1

Rs.74.00

Euro

1

Rs.64.48

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

5

PAID-UP CAPITAL

1~10

3

OPERATING SCALE

1~10

3

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

2

--PROFITABILIRY

1~10

2

--LIQUIDITY

1~10

3

--LEVERAGE

1~10

3

--RESERVES

1~10

2

--CREDIT LINES

1~10

3

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

YES

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

26

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

-

NB

                                       New Business

-

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.